Dr Peter Fitzgerald is the founder and managing director of Randox Laboratories, a global leader in diagnostic healthcare solutions. Dr Fitzgerald established the company with a vision to advance medical science through innovation, research, and high-quality diagnostic testing. Under his leadership, Randox has grown into an internationally recognised organisation, supporting healthcare systems, clinical research, and public health initiatives worldwide. Dr Fitzgerald is widely regarded for his commitment to scientific excellence and the development of cutting-edge diagnostic technologies.

1. What is your organisation's role and core operations within the laboratory industry. Please give us an overview of your presence and impact in the regions you are active in, with focus on the GCC.

Randox Laboratories is a global leader in the in-vitro diagnostics (IVD) industry, specialising in the research, development, manufacture and distribution of innovative diagnostic solutions. Founded in 1982, the organisation offers a comprehensive portfolio including diagnostic reagents, analysers, quality control materials, external quality assessment (EQA) programmes, and advanced molecular and biochip technologies. Its patented biochip technology enables the simultaneous detection of multiple analytes from a single sample, supporting faster, accurate and cost-effective testing. Randox operates across clinical, research, veterinary, food safety, forensic and toxicology laboratories, supporting healthcare professionals in improving disease detection, monitoring and patient outcomes. 

A strong culture of innovation underpins the organisation, with sustained investment in research and development to address evolving global healthcare needs. With a broad international footprint, Randox supplies products to over 145 countries through direct operations and established distribution partners. In the Gulf Cooperation Council (GCC) region, Randox continues to strengthen its presence through close collaboration with regional laboratories, healthcare providers and distributors. Its diagnostic solutions support the region’s expanding healthcare infrastructure by enhancing laboratory efficiency, enabling early disease detection and maintaining high quality standards. Through participation in key industry events such as WHX Labs Dubai and strong regional partnerships, Randox contributes to the ongoing development of laboratory medicine and improved patient care across the GCC.

2. In your opinion, what key market dynamics, technological advances, and operational challenges are currently reshaping the laboratory industry and its sub-sectors? What are your predictions over the next decade?

The laboratory industry is undergoing significant transformation, driven by evolving market dynamics, rapid technological innovation and increasing operational complexity. One of the most prominent market drivers is the growing demand for early and accurate disease detection, supported by ageing populations, rising chronic disease prevalence and greater emphasis on preventive healthcare. At the same time, laboratories are under pressure to deliver faster turnaround times while maintaining high standards of quality and cost efficiency. Technological advances are playing a central role in reshaping the sector. 

Automation, digitalisation and data integration are improving laboratory workflows and reducing manual error, while molecular diagnostics and multiplex testing technologies are enabling more comprehensive insights from smaller sample volumes. The increasing use of artificial intelligence and advanced analytics is also enhancing result interpretation, quality management and predictive diagnostics. Operationally, laboratories face challenges including workforce shortages, regulatory complexity, supply chain resilience and the need for continual investment in new technologies. Balancing innovation with affordability and scalability remains a key concern, particularly across diverse healthcare systems and regions. Looking ahead to the next decade, the industry is expected to see continued growth in decentralised and point-of-care testing, greater integration of diagnostics with digital health platforms, and increased reliance on high-throughput, multi-analyte technologies. Laboratories that successfully adopt automation, embrace innovation and maintain strong quality frameworks will be best positioned to meet future healthcare demands.

3. How does your organisation drive innovation and advance research and development within this space? Please highlight some of your most significant recent achievements or current breakthrough projects.

Innovation and research and development are central to Randox Laboratories’ strategy. The organisation maintains a strong focus on in-house research, supported by multidisciplinary teams of scientists, engineers and clinicians developing next-generation diagnostic and quality solutions. A significant proportion of annual revenue is reinvested into R&D to ensure a continuous pipeline of innovations that address evolving laboratory and clinical needs. Randox’s proprietary biochip technology remains a core driver of innovation, enabling multiplex testing that delivers comprehensive diagnostic insights from a single sample, improving efficiency and supporting earlier clinical decision-making. Innovation also extends to quality assurance. 

In 2025, Randox launched three new external quality assessment (EQA) programmes covering pre-eclampsia, Chagas disease and blood typing, addressing critical and emerging diagnostic priorities. A major breakthrough achievement is the development of the world’s first independent internal quality control (IQC) and global EQA scheme for performance review of assays used in the determination of pre-eclampsia in pregnancy. This programme is also the first of its kind to achieve IVDR CE marking for a multianalyte quality control of this nature, representing a significant advancement in maternal health diagnostics.

4. What strategies has your organisation implemented to maintain the highest standards of excellence in this field?

Maintaining the highest standards of excellence is fundamental to Randox Laboratories' operations and long-term success. The organisation achieves this through a strong commitment to quality, innovation, regulatory compliance and continuous improvement across all areas of the business. Robust quality management systems are embedded throughout the product lifecycle, from research and development through to manufacturing, validation and post-market support, ensuring consistent performance and reliability. Randox places significant emphasis on meeting and exceeding international regulatory and accreditation standards, including IVDR requirements, to ensure its solutions meet the highest levels of clinical and analytical confidence. Continuous monitoring, validation and performance review are supported through Randox’s quality control and external quality assessment (EQA) programmes, which enable laboratories worldwide to benchmark and enhance their testing accuracy. Investment in people is another key pillar of excellence. 

Randox fosters a culture of scientific rigour, professional development and cross-functional collaboration, ensuring teams remain at the forefront of diagnostic and quality expertise. Ongoing training and knowledge-sharing initiatives support consistent standards across global operations. In addition, Randox works closely with customers, academic institutions and industry partners to incorporate real-world insights into product development and service delivery. By combining strong governance, technological leadership and customer-focused collaboration, Randox continues to uphold excellence and support trusted, high-quality laboratory diagnostics worldwide.

5. What are you looking forward to at WHX Labs Dubai 2026. If applicable, please give us an overview of the cutting-edge solutions or innovations your organisation is preparing to unveil at the show.

Randox Laboratories maintains the highest standards of excellence through continual innovation in quality management, exemplified by the development and launch of its new digital platform, RIQAS.com. The platform represents a major strategic advancement in how laboratories manage, analyse and benchmark quality performance, reinforcing Randox’s long-standing commitment to diagnostic excellence and data-driven decision-making. RIQAS.com has been designed to provide laboratories with a modern, intuitive and secure software environment that enables real-time access to quality performance data across internal quality control (IQC) and external quality assessment (EQA) programmes. 

Through advanced analytics, automated reporting and global benchmarking capabilities, the platform allows laboratories to identify trends, address performance issues proactively and maintain consistent testing accuracy across sites and systems. The development of RIQAS.com was shaped by extensive user feedback and close collaboration with laboratory professionals worldwide, ensuring the platform meets real operational needs while remaining scalable and future-ready. Robust validation, cybersecurity and compliance measures are embedded to support regulatory requirements and protect data integrity. RIQAS.com will be showcased at WHX Labs Dubai 2026, highlighting Randox’s commitment to digital innovation and engagement with the global laboratory community. By combining advanced software engineering with established quality expertise, Randox enables laboratories to strengthen governance, improve operational efficiency and uphold the highest standards of analytical performance worldwide.

6. Is there anything else you would like to add?

Randox is committed to improving healthcare worldwide and remains at the forefront of advanced diagnostics, recognising the essential role this sector plays in delivering earlier, more accurate disease detection and better patient outcomes. Through sustained investment in research, innovation and quality, Randox develops diagnostic solutions that support clinicians in making informed decisions and enable laboratories to operate with greater efficiency. 

By helping to streamline testing processes and improve diagnostic confidence, Randox contributes to reducing the pressures, inefficiencies and rising costs that continue to challenge healthcare systems globally, supporting more sustainable models of care.